AGAna Guerrero

Ana Guerrero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Guerrero has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Jesús Gil

    Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK

    6 shared publications
  • Juan Zalvide

    Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain

    4 shared publications
  • Cristina Iglesias

    Departamento de Fisioloxía and Centro de Investigación en Medicina Molecular e Enfermedades Crónicas (CIMUS), Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela, Avda de Barcelona s/n, 15706 A, Santiago de Compostela, Coruña, Spain

    3 shared publications
  • Andrew J. Innes

    Centre for Haematology, Department of Immunology and Inflammation Faculty of Medicine, Imperial College London London UK

    2 shared publications
  • Anthony G. Uren

    MRC London Institute of Medical Sciences (LMS), Du Cane Road, London, W12 0NN, UK.

    2 shared publications
  • Antoni Olona

    Centre for Inflammatory Disease Imperial College London, Hammersmith Hospital London UK

    2 shared publications

Latest Publications

  • Nucleosome disruption by 5‐bromodeoxyuridine leads to senescence

    by Ana Guerrero

    5‐Bromodeoxyuridine (BrdU) exposure leads to senescence, but the mechanistic details remain elusive. In this issue, En A et al. unveil a role of the HBR domain in histone H2B as a potential mediator of the effects of BrdU both in yeast and in human cells.Comment on: https://doi.org/10.1111/febs.16584


  • Open Access

    3-Deazaadenosine alleviates senescence to promote cellular fitness and cell therapy efficiency in mice

    by Ana Guerrero, Andrew J. Innes, Pierre-François Roux, Sonja C. Buisman, Johannes Jung, Laura Ortet, Victoria Moiseeva, Verena Wagner, Lucas Robinson, Albertina Ausema, et al.

    Cellular senescence is a stable type of cell cycle arrest triggered by different stresses. As such, senescence drives age-related diseases and curbs cellular replicative potential. Here, we show that 3-deazaadenosine (3DA), an S-adenosyl homocysteinase inhibitor, alleviates replicative and oncogene-induced senescence. 3DA-treated senescent cells showed reduced global histone H3 lysine 36 trimethylation, an epigenetic modification that marks the bodies of actively transcribed genes. By integrating transcriptome and epigenome data, we demonstrate that 3DA treatment affects key factors of the senescence transcriptional program. Notably, 3DA treatment alleviated senescence and increased the proliferative and regenerative potential of muscle stem cells from very old mice in vitro and in vivo. Moreover, ex vivo 3DA treatment was sufficient to enhance the engraftment of human umbilical cord blood cells in immunocompromised mice. Together, our results identify 3DA as a promising drug enhancing the efficiency of cellular therapies by restraining senescence.


  • Top Cited Papers

    Cellular senescence at the crossroads of inflammation and Alzheimer's disease

    by Ana Guerrero, Bart De Strooper, I. Lorena Arancibia-Cárcamo


  • Open Access

    Cardiac glycosides cause cytotoxicity in human macrophages and ameliorate white adipose tissue homeostasis

    by Antoni Olona, Charlotte Hateley, Ana Guerrero, Jeong‐Hun Ko, Michael R. Johnson, Paras K. Anand, David Thomas, Jesus Gil, Jacques Behmoaras

    Background and Purpose: Cardiac glycosides inhibit Na+/K+‐ATPase and are used to treat heart failure and arrhythmias. They can induce inflammasome activation and pyroptosis in macrophages, suggesting cytotoxicity, which remains to be elucidated in human tissues.Experimental Approach: To determine the cell‐type specificity of this cytotoxicity, we used human monocyte‐derived macrophages and non‐adherent peripheral blood cells from healthy donors, plus omental white adipose tissue, stromal vascular fraction‐derived pre‐adipocytes and adipocytes from obese patients undergoing bariatric surgery. All these cells/tissues were treated with nanomolar concentrations of ouabain (50, 100, 500 nM) to investigate the level of cytotoxicity and the mechanisms leading to cell death. In white adipose tissue, we investigated ouabain‐mediated cytotoxicity by measuring insulin sensitivity, adipose tissue function and extracellular matrix deposition ex vivo.Key Results: Ouabain induced cell death through pyroptosis and apoptosis, and was more effective in monocyte‐derived macrophages compared to non‐adherent peripheral blood mononuclear cell populations. This cytotoxicity is dependent on K+ flux, as ouabain causes intracellular depletion of K+ and accumulation of Na+ and Ca2+. Consistently, the cell death caused by these ion imbalances can be rescued by addition of potassium chloride to human monocyte‐derived macrophages. Remarkably, when white adipose tissue explants from obese patients are cultured with nanomolar concentrations of ouabain, this causes depletion of macrophages, down‐regulation of type VI collagen levels and amelioration of insulin sensitivity ex vivo.Conclusion and Implications: The use of nanomolar concentration of cardiac glycosides could be an attractive therapeutic treatment for metabolic syndrome, characterized by pathogenic infiltration and activation of macrophages.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc


  • Open Access

    Galactose‐modified duocarmycin prodrugs as senolytics

    by Ana Guerrero, Romain Guiho, Nicolás Herranz, Anthony Uren, Dominic J. Withers, Juan Pedro Martínez‐Barbera, Lutz F. Tietze, Jesús Gil

    Senescence is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with cancer, fibrosis and many age‐related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence‐associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal β‐galactosidase, and this has been exploited as a marker for senescence (senescence‐associated β‐galactosidase activity). Consequently, we hypothesized that galactose‐modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose‐modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal β‐galactosidase (GLB1)‐dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole‐body irradiation treatment of mice. Moreover, taking advantage of a mouse model of adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD prodrug selectively reduced the number of β‐catenin‐positive preneoplastic senescent cells. In summary, the above results make a case for testing the potential of galactose‐modified duocarmycin prodrugs to treat senescence‐related pathologies.


  • Cardiac glycosides are broad-spectrum senolytics

    by Ana Guerrero, Nicolás Herranz, Bin Sun, Verena Wagner, Suchira Gallage, Romain Guiho, Katharina Wolter, Joaquim Pombo, Elaine E. Irvine, Andrew J. Innes, et al.

    Senescence is a cellular stress response that results in the stable arrest of old, damaged or pre-neoplastic cells. Oncogene-induced senescence is tumour suppressive but can also exacerbate tumorigenesis through the secretion of proinflammatory factors from senescent cells. Drugs that selectively kill senescent cells, termed ‘senolytics’, have proved beneficial in animal models of many age-associated diseases. In the present study, we show that the cardiac glycoside ouabain is a senolytic agent with broad activity. Senescent cells are sensitized to ouabain-induced apoptosis, a process mediated in part by induction of the proapoptotic Bcl-2 family protein NOXA. We demonstrate that cardiac glycosides synergize with anti-cancer drugs to kill tumour cells and eliminate senescent cells that accumulate after irradiation or in old mice. Ouabain also eliminates senescent pre-neoplastic cells. The findings of the present study suggest that cardiac glycosides may be effective anti-cancer drugs by acting through multiple mechanisms. Given the broad range of senescent cells targeted by cardiac glycosides, their use against age-related diseases warrants further exploration.


  • Open Access

    Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma

    by Jose Mario Gonzalez-Meljem, Scott Haston, Gabriela Carreno, John R. Apps, Sara Pozzi, Christina Stache, Grace Kaushal, Alex Virasami, Leonidas Panousopoulos, Seyedeh Neda Mousavy-Gharavy, et al.

    Senescent cells may promote tumour progression through the activation of a senescence-associated secretory phenotype (SASP), whether these cells are capable of initiating tumourigenesis in vivo is not known. Expression of oncogenic β-catenin in Sox2+ young adult pituitary stem cells leads to formation of clusters of stem cells and induction of tumours resembling human adamantinomatous craniopharyngioma (ACP), derived from Sox2− cells in a paracrine manner. Here, we uncover the mechanisms underlying this paracrine tumourigenesis. We show that expression of oncogenic β-catenin in Hesx1+ embryonic precursors also results in stem cell clusters and paracrine tumours. We reveal that human and mouse clusters are analogous and share a common signature of senescence and SASP. Finally, we show that mice with reduced senescence and SASP responses exhibit decreased tumour-inducing potential. Together, we provide evidence that senescence and a stem cell-associated SASP drive cell transformation and tumour initiation in vivo in an age-dependent fashion.


  • The MST3/STK24 kinase mediates impaired fasting blood glucose after a high-fat diet

    by Cristina Iglesias, Ebel Floridia, Miriam Sartages, Begoña Porteiro, María Fraile, Ana Guerrero, Diana Santos, Juan Cuñarro, Sulay Tovar, Rubén Nogueiras, et al.

    The identification of mediators in the pathogenesis of type 2 diabetes mellitus is essential for the full understanding of this disease. Protein kinases are especially important because of their potential as pharmacological targets. The goal of this study was to investigate whether mammalian sterile-20 3 (MST3/STK24), a stress-regulated kinase, is involved in metabolic alterations in obesity.


  • Open Access

    HMGB2 holds the key to the senescence-associated secretory phenotype

    by Ana Guerrero, Jesús Gil

    The senescence-associated secretory phenotype (SASP) is a hallmark of senescence with an important physiological impact, but how it is established is unclear. In this issue, Aird et al. (2016. J. Cell Biol. https://doi.org/10.1083/jcb.201608026) describe how chromatin-bound HMGB2 fine tunes SASP expression by avoiding heterochromatin spreading.


  • Open Access

    The cerebral cavernous malformation 3 gene is necessary for senescence induction

    by Ana Guerrero, Cristina Iglesias, Selina Raguz, Ebel Floridia, Jesús Gil, Celia M. Pombo, Juan Zalvide

    Mutations in cerebral cavernous malformation 3 gene are known to result in development of vascular malformations and have recently been proposed to also give rise to meningiomas. We report in this study that lack of CCM3 unexpectedly impairs the senescence response of cells, and this is related to the inability of CCM3-deficient cells to induce the C/EBPβ transcription factor and implement the senescence-associated secretory phenotype. Induction of C/EBPβ and cytokines is also impaired in the absence of CCM3 in response to cytokines in nonsenescent cells, pointing to it being a primary defect and not secondary to impaired senescence. CCM3-deficient cells also have a defect in autophagy at late passages of culture, and this defect is also not dependent on impaired senescence, as it is evident in immortal cells after nutrient starvation. Further, these two defects may be related, as enforcing autophagy in CCM3-deficient late passage cells increases C/EBPβ cytokine expression. These results broaden our knowledge on the mechanisms by which CCM3 deficiency results in disease and open new avenues of research into both CCM3 and senescence biology.